# Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients

> **NCT03351361** · PHASE3 · COMPLETED · sponsor: **Rennes University Hospital** · enrollment: 217 (actual)

## Conditions studied

- Advanced Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Nivolumab + Ipilimumab
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03351361
- **Lead sponsor:** Rennes University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-02-19
- **Primary completion:** 2021-07-31
- **Final completion:** 2022-07-31
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2023-03-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03351361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03351361, "Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03351361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*